These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10211135)

  • 1. Cognitive deficit in schizophrenia and its neurochemical basis.
    Breier A
    Br J Psychiatry Suppl; 1999; (37):16-8. PubMed ID: 10211135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
    Bilder RM; Goldman RS; Volavka J; Czobor P; Hoptman M; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Kunz M; Chakos M; Cooper TB; Horowitz TL; Lieberman JA
    Am J Psychiatry; 2002 Jun; 159(6):1018-28. PubMed ID: 12042192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.
    Meltzer HY; McGurk SR
    Schizophr Bull; 1999; 25(2):233-55. PubMed ID: 10416729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive function in schizophrenic patients.
    Tollefson GD
    J Clin Psychiatry; 1996; 57 Suppl 11():31-9. PubMed ID: 8941169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
    Purdon SE; Jones BD; Stip E; Labelle A; Addington D; David SR; Breier A; Tollefson GD
    Arch Gen Psychiatry; 2000 Mar; 57(3):249-58. PubMed ID: 10711911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neuroleptics and cognition].
    Brunnauer A; Geiger E; Laux G
    Psychiatr Prax; 2003 May; 30 Suppl 2():S106-9. PubMed ID: 14509053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients].
    Briken P; Nika E; Krausz M; Naber D
    Fortschr Neurol Psychiatr; 2002 Mar; 70(3):139-44. PubMed ID: 11880946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics.
    Han M; Zhang XY; Chen DC; Tan YL; Song CS; Yu YH; Huang XF
    Int Clin Psychopharmacol; 2015 Mar; 30(2):89-95. PubMed ID: 25568968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
    Light GA; Geyer MA; Clementz BA; Cadenhead KS; Braff DL
    Am J Psychiatry; 2000 May; 157(5):767-71. PubMed ID: 10784470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of risperidone and olanzapine on the indications for clozapine.
    Ganguli R; Brar JS
    Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical neuroleptics in child and adolescent psychiatry.
    Remschmidt H; Hennighausen K; Clement HW; Heiser P; Schulz E
    Eur Child Adolesc Psychiatry; 2000; 9 Suppl 1():I9-19. PubMed ID: 11140784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schizophrenia treatment: the use of atypical drugs--risperdal, zyperexa, and clozaril.
    Kalinyak CM
    Int J Psychiatr Nurs Res; 1998 Sep; 4(2):445-51. PubMed ID: 10451301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotics and cognition in schizophrenia.
    Sharma T
    Arch Gen Psychiatry; 2002 Jun; 59(6):571-2; author reply 573-5. PubMed ID: 12044209
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical efficacy of olanzapine].
    Yui K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Jul; 19(3):101-10. PubMed ID: 10495984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive improvement in schizophrenia with novel antipsychotic medications.
    Purdon SE
    Schizophr Res; 1999 Mar; 35 Suppl():S51-60. PubMed ID: 10190225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia.
    Bilici M; Cakirbay H; Guler M; Tosun M; Ulgen M; Tan U
    Int J Neurosci; 2002 Jul; 112(7):817-28. PubMed ID: 12424822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.
    Brown JW; Rueter LE; Zhang M
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():53-62. PubMed ID: 24269664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication.
    Moritz S; Woodward TS; Krausz M; Naber D;
    Int Clin Psychopharmacol; 2002 Jan; 17(1):41-4. PubMed ID: 11800506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of antipsychotic drugs.
    Gupta S
    Am J Psychiatry; 2003 Mar; 160(3):591; author reply 592-3. PubMed ID: 12611855
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.